Effect of Ponesimod, a Selective S1P1 Receptor Modulator, on the QT Interval in Healthy Individuals

• Published in: Basic & clinical pharmacology & toxicology Vol. 116; no. 5; pp. 429 - 437
• Main Authors: Hoch, Matthias, Darpo, Borje, Brossard, Patrick, Zhou, Meijian, Stoltz, Randall, Dingemanse, Jasper
• Format: Journal Article
• Language: English
• Published: England Wiley Subscription Services, Inc 01.05.2015
• Subjects: Action Potentials; Adolescent; Adult; Confidence intervals; Cross-Over Studies; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug therapy; Electrocardiography; Female; Fluoroquinolones - adverse effects; Healthy Volunteers; Heart Conduction System - drug effects; Heart Conduction System - physiopathology; Heart Rate - drug effects; Humans; Long QT Syndrome - chemically induced; Long QT Syndrome - physiopathology; Male; Middle Aged; Receptors, Lysosphingolipid - drug effects; Receptors, Lysosphingolipid - metabolism; Risk Assessment; Thiazoles - administration & dosage; Thiazoles - adverse effects; Thiazoles - pharmacokinetics; Time Factors; Young Adult

Ponesimod is an orally active selective sphingosine‐1‐phosphate receptor 1 modulator under investigation for the treatment of multiple sclerosis. This was a single‐centre, double‐blind, randomized, placebo‐ and positive‐controlled parallel‐group study investigating the effects of ponesimod on the QT...